ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
Recently Viewed
You have not visited any articles yet, Please visit some articles to see contents here.
CONTENT TYPES

Figure 1Loading Img
RETURN TO ISSUEPREVPhysical Insights in...Physical Insights into Materials and Molecular PropertiesNEXT

Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America

  • Rui Wang
    Rui Wang
    Department of Mathematics, Michigan State University, East Lansing, Michigan 48824, United States
    More by Rui Wang
  • Jiahui Chen
    Jiahui Chen
    Department of Mathematics, Michigan State University, East Lansing, Michigan 48824, United States
    More by Jiahui Chen
  • , and 
  • Guo-Wei Wei*
    Guo-Wei Wei
    Department of Mathematics, Michigan State University, East Lansing, Michigan 48824, United States
    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, United States
    Department of Electrical and Computer Engineering, Michigan State University, East Lansing, Michigan 48824, United States
    *Email: [email protected]
    More by Guo-Wei Wei
Cite this: J. Phys. Chem. Lett. 2021, 12, 49, 11850–11857
Publication Date (Web):December 7, 2021
https://doi.org/10.1021/acs.jpclett.1c03380
Copyright © 2021 American Chemical Society
Article Views
3455
Altmetric
-
Citations
LEARN ABOUT THESE METRICS
Read OnlinePDF (8 MB)
Supporting Info (2)»

Abstract

Abstract Image

The importance of understanding SARS-CoV-2 evolution cannot be overlooked. Recent studies confirm that natural selection is the dominating mechanism of SARS-CoV-2 evolution, which favors mutations that strengthen viral infectivity. Here, we demonstrate that vaccine-breakthrough or antibody-resistant mutations provide a new mechanism of viral evolution. Specifically, vaccine-resistant mutation Y449S in the spike (S) protein receptor-binding domain, which occurred in co-mutations Y449S and N501Y, has reduced infectivity compared to that of the original SARS-CoV-2 but can disrupt existing antibodies that neutralize the virus. By tracking the evolutionary trajectories of vaccine-resistant mutations in more than 2.2 million SARS-CoV-2 genomes, we reveal that the occurrence and frequency of vaccine-resistant mutations correlate strongly with the vaccination rates in Europe and America. We anticipate that as a complementary transmission pathway, vaccine-breakthrough or antibody-resistant mutations, like those in Omicron, will become a dominating mechanism of SARS-CoV-2 evolution when most of the world’s population is either vaccinated or infected. Our study sheds light on SARS-CoV-2 evolution and transmission and enables the design of the next-generation mutation-proof vaccines and antibody drugs.

The log 2 enrichment ratio is collected from the experimental deep mutation enrichment data in ref (30).

Supporting Information

ARTICLE SECTIONS
Jump To

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jpclett.1c03380.

  • Names of antibodies disrupted by mutations (S6.0.1: antibodies_disruptmutation.csv), PDB entries for all of the 130 SARS-CoV-2 antibodies (S6.0.2: antibodies.csv), all of the SNPs of RBD co-mutations by October 20, 2021 (S6.0.3: RBD_comutation_residue_10202021.csv), and all of the nondegenerate RBD co-mutations with their frequencies, antibody disruption counts, total BFE changes, and first detection dates and countries (S6.0.4: Track_Comutation_10202021.xlsx) (ZIP)

  • Data preprocessing and feature generation methods (section S1), machine learning methods (section S2), validations of our machine learning predictions with experimental data (section S3), the top 30 most observed S protein RBD mutations by October 20, 2021 (section S4), time evolution of the vaccination rate and the frequency of the Y449S mutation in CH and RO from December 26, 2020, to October 22, 2021 (section S5), and titles of tables of supplementary data (section S6) (PDF)

Terms & Conditions

Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

Cited By

This article is cited by 3 publications.

  1. Jiahui Chen, Rui Wang, Yuta Hozumi, Gengzhuo Liu, Yuchi Qiu, Xiaoqi Wei, Guo-Wei Wei. Emerging Dominant SARS-CoV-2 Variants. Journal of Chemical Information and Modeling 2023, 63 (1) , 335-342. https://doi.org/10.1021/acs.jcim.2c01352
  2. Kaifu Gao, Rui Wang, Jiahui Chen, Limei Cheng, Jaclyn Frishcosy, Yuta Huzumi, Yuchi Qiu, Tom Schluckbier, Xiaoqi Wei, Guo-Wei Wei. Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. Chemical Reviews 2022, 122 (13) , 11287-11368. https://doi.org/10.1021/acs.chemrev.1c00965
  3. Jiahui Chen, Rui Wang, Nancy Benovich Gilby, Guo-Wei Wei. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. Journal of Chemical Information and Modeling 2022, 62 (2) , 412-422. https://doi.org/10.1021/acs.jcim.1c01451

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect

This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. Read the ACS privacy policy.

CONTINUE